Pooled analysis reported statistically significant effect on total stroke outcomes from treatment with GLP-1RA versus placebo [RR=0.83, 95%CI(0.73, 0.95), p =0.005], showed that the risk of total stroke was about 17% lower in the GLP-1RA treatment group than the placebo group
Taurine ameliorated homocysteine-induced H9C2 cardiomyocyte apoptosis by modulating endoplasmic reticulum stress
As the first orally administered GLP-1RA, oral semaglutide broadens the options available to patients and healthcare providers who may have expressed reluctance to use injectables [3, 37,38,39]
Call 512-443-3000 To Schedule Your Appointment
12 mg target dose (TRIUMPH-1, TRIUMPH-2, TRIUMPH-4) 9 mg target dose (TRIUMPH-1, TRIUMPH-2, TRIUMPH-4) 4 mg target dose (TRIUMPH-1, TRIUMPH-2 only) What changed from Phase 2 to Phase 3 The key differences in the Phase 3 titration schedule: 6 mg intermediate step added